🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
94.54
+2.62 (2.85%)
At close: Nov 18, 2026, 4:00 PM EST
96.00
+1.46 (1.54%)
After-hours: Nov 18, 2026, 7:39 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Cardiopulmonary and epilepsy growth is supported by Essenz conversions, procedure demand, reimbursement and CORE-VNS evidence. Planned 2027 launches and OSA scaling from 2028 underpin the margin and revenue outlook; depression data showed 80% responder durability at three years.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Okay, we are ready to get started with our next session here this morning at the Jefferies London Healthcare Conference. I am Matt Taylor, the U.S. Medical Supplies and Devices Analyst here at Jefferies, and pleased to welcome the management team from LivaNova. We will have about 25 minutes for a spirited Q&A. We have Alex Shvartsburg, who is the CFO, and Ahmet Tezel, the Chief Innovation Officer. I would like to start, guys, just by giving a little bit of a high-level overview of the LivaNova portfolio, maybe talk about your competitive positioning in both cardiopulmonary and epilepsy, and just talk about how the core business has been performing in those markets.

Alex Shvartsburg
CFO, LivaNova

Yeah. For those who are newer to our story, we are a Global Medtech company with nearly 50 years of experience in two very strong and very well-performing businesses. We call it our core in cardiopulmonary and epilepsy. Both market-leading positions in both segments. Cardiopulmonary has been a strong growth driver over the last three years, delivering double-digit growth, really driven by several elements. One is we launched a new product in 2023, which is our Essenz capital equipment heart-lung machine. The conversion cycle has been going really well, and we continue to see that as a growth driver going into next year and beyond. We have a market-leading position in capital equipment, about a 70% market share in the overall heart-lung machine installed base. We are about 20% of the way through in upgrading that installed base. So it is going to be a multi-year conversion cycle.

This year, we are going to exit with Essenz representing about 80% of total placements. Next year, going to 100%. Every machine next year will be our Essenz platform. The next growth driver in CP is really our consumables business, and specifically the oxygenator business, which has We have grown our market share from about 30% to about 40% over the last several years. The segment has actually, from a procedure volume standpoint, continues to perform very well. We see that segment growing at about a mid-single-digit level. Historically, it has been flattish to about low single-digit growth in the developed markets. That has actually accelerated over the last few years. Part of it is just pure demographics.

The other part is, I think a lot of patients who historically have received a TAVR procedure are now coming back, are not necessarily good candidates for a replacement TAVR, so they come into a surgical heart valve procedure. So sort of a revision that has accelerated the growth in the developed markets. In the developing markets, basically access to healthcare continues to improve, so that has enabled faster growth. We continue to perform extremely well across both the capital equipment as well as the consumables segment. So that is the CP business. In Epilepsy, we have a market-leading position in our neuromodulation technology. We have been in this space for about 30 years, and continue to drive penetration into what is an under-penetrated market segment today. In the U.S., there is approximately 1 million patients diagnosed with DRE. About 10% of those patients are treated with interventional therapies like VNS.

Every year, there is about 900,000 patients diagnosed with DRE across the world, and we have barely scratched the surface of driving penetration in that space. The growth in epilepsy has really accelerated over the course of the last two years. This year specifically driven by improvements in reimbursement in the U.S., where CMS has lifted the reimbursement rates for both new patients and replacement segments by nearly 50%. That has driven growth where hospitals historically who have been sort of challenged by the economics of VNS Therapy, that has improved, and that has helped the growth. Our CORE-VNS clinical data, which has recently been published, has actually gained traction and has really accelerated the volume and really driven the penetration of VNS Therapy. We are pleased with our performance to date.

We see our business as having really strong durable growth over the next several years, which we described at our investor day. We are heading in the right direction.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

It has been producing really exciting growth, kind of low double digit, including you recently upgrading your guidance to 9%-10% for this year. Maybe you could talk a little bit more about the sustainability of that growth as we move into 2027, and what are some of the key puts and takes that people should think about?

Alex Shvartsburg
CFO, LivaNova

Same growth drivers will stay intact over the next several years. We also have some innovation that is coming down the pike. Maybe turn it over to Ahmet a little bit to talk about some of what is coming.

Ahmet Tezel
Chief Innovation Officer, LivaNova

Sure. I mean, in each of our business units, we have significant innovation coming. I will start with epilepsy. Next year, we are launching our next-generation implant. It solves the fundamental workflow challenge of today's technology, so it is a significant upgrade. It is not just an iterative upgrade. We have our sleep apnea launch next year as well. We believe the clinical differentiation is extremely strong. The clinical trial had the highest responder rate with the most severe patients enrolled with no exclusions amongst the other available technologies. On the CP side, we have two auxiliary equipment launches. When you do heart-lung machine, there is a third device that does the management of the temperature of the blood, which is called a heater-cooler, and another device does the management of the gases, oxygen and carbon dioxide, which is called the Air Manager.

Today, when you buy a heart-lung machine from LivaNova, you buy Essenz, the actual device, but it comes with the previous generation heater-cooler and Air Manager, so we will upgrade those next year. They will come with a price premium as well. In 2028, we are launching our next-generation oxygenator, which we are very excited about because it is clinically differentiated, and obviously, that will also come with a price premium.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Very good. Let us talk a little bit about how this plays into your margin goals. You talked about the LRP kind of in phases with an expectation to keep operating margins kind of in the low 20s as we move into 2027, but then seeing some inflection really from the sleep launch as we move towards the end of the decade. How should we think about the phasing of the margins as you move through investment period to ramp period, and what could the cadence be like over the next couple years?

Alex Shvartsburg
CFO, LivaNova

Yeah, so during our investor day, we kind of outlined these two phases of our financial framework. The first phase is really about driving top-line growth in mid to high single digits and really growing EPS in line with our top-line growth. So, we drew the line at 20% margin, and basically, any margin expansion that we get from CP or epilepsy, we expect about 300 basis points of margin expansion in CP over the next several years, and about 200 basis points coming from epilepsy. That margin growth will be reinvested in standing up the OSA commercial channels. These are components of our business that we do not have today, so all that excess margin will be reinvested in sleep apnea. Then as sleep apnea scales, so 2028 through 2030, we will expect to generate a fair amount of P&L leverage from that.

We guided sleep apnea to $200 million-$400 million in revenue by 2030. Obviously, the gross margins in Neuromod are very attractive, and so that will drive significant P&L leverage and get us to an operating margin profile in the mid-20s and beyond. So, gives us an opportunity to really leverage our infrastructure that we have built for both epilepsy and CP businesses. You think about a Neuromod platform, that is why I kind of love the platform technology. We are able to leverage our capabilities in R&D, in our supply chain, commercial operations, as well as back office. All of that fixed infrastructure is there to take advantage in driving growth for OSA and hopefully DTD someday.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Ahmet, maybe we could talk a little bit more about the clinical differentiation in sleep. You referenced the high responder rates, and also made some upgrades to the form factor as you go to market, improving the recharge burden and the MRI safety. I think one of the really interesting angles is the PolySync algorithm that you have. Maybe you could expound on that and some of the results you are seeing there, and how you hope that might differentiate you further in the market.

Ahmet Tezel
Chief Innovation Officer, LivaNova

Yeah, sure. One of the main differences of our technology is that we put the electrodes to the proximal end of the nerve, which means we control broader muscle groups compared to other technologies that control the airway. We do not just protrude the tongue, we also strengthen the airway. The way we do that is that we have actually six electrodes, and you can tune the electrodes to adjust different muscles through the hypoglossal nerve. In the original trial, we did not have the algorithms to optimize how you utilize these electrodes. They were utilized, not all six of them, and they were utilized sequentially. Electrode one will turn on, and then electrode four will turn on, for example. Once we had the original data, with that, we achieved 65% responder rate, which is comparable to the market leader today.

But one difference was that we enrolled more severe patients, higher BMI, higher starting baseline, apnea-hypopnea index, or the severity of the disease, and we did not exclude CCC patients. We took all comers. Despite that, originally, we achieved 65% responder rate. Then what we did is that once we had that data group, we essentially developed new algorithms utilizing the data from the original patient population and developed what we call PolySync. What PolySync does is that instead of sequentially providing current, it combines, and the electrodes work together at the same time. When you do that, you create a different electrical effect. Instead of electrode one and three turning one after each other, they turn on together. Now we can predict what you need to do for each patient, and we call that algorithm PolySync algorithm.

What we did is that we brought patients that were non-responders and utilized PolySync, and we converted them to be responders. In our trial now, we demonstrated through the FDA trial that we have about 85% responder rate compared to 60s with other trials. What that really means is that today, if you are getting hypoglossal nerve stimulation, there is one in three chance that you are not going to be a good responder. With our technology, that one in three is down to one in seven. What we hear from physicians is that that is a fundamental change, because this is an expensive surgery, and telling a patient, "You know, two out of three, you are going to get a good response," versus, "You are going to get six out of seven good response," is a big difference.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Maybe we could talk through that goal to get to $200 million-$400 million in 2030. I guess, how much of that do you think is really dependent on the clinical differentiation? Could you talk about how you might go to market initially with the differentiation on the label and being able to treat more of these patients who really were untreatable before?

Alex Shvartsburg
CFO, LivaNova

Maybe want to talk a little bit about our trial and sort of the patient base and how that really drove the differentiation.

Ahmet Tezel
Chief Innovation Officer, LivaNova

Yeah. I mean, so today, if you are a CCC patient, these are the most severe patients. You are going to be contraindicated, or there is a warning on the label. With us, on day one, all comers are welcome. That automatically, CCC patients are about 25%-30% of the general population. So automatically on day one, the market for us is slightly larger. We will not necessarily go after just those patients, but it does create a differentiation to be able to say, "Hey, you do not need to be excluded."

First, we need to figure out if you have CCC or not, and if you do, you will be excluded as one alternative, versus with our technology, it does not matter. All comers are welcome. That is why we are very excited that we will have that clinical differentiation from time zero. On top of that non-exclusion, the high responder rate that we achieve is why we believe this is a really good alternative.

Alex Shvartsburg
CFO, LivaNova

I think also, the OSPREY trial enrolled some of the more challenging patients. From a BMI perspective, we enrolled patients with higher BMI. We saw comparable results with the entirety of our patient base. I think that clinical differentiation is what is going to truly differentiate us from a competitive perspective. As Ahmet mentioned, CCC essentially expands the total available market to us. That is another element that gives us confidence that we can ultimately scale this business to our target.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Maybe going back to epilepsy, you mentioned the good longer-term data from CORE-VNS and the upgraded reimbursement. Can you talk about how that's playing into both volume and your ability to take price in the market now that the hospitals are no longer losing money on some of the procedures?

Alex Shvartsburg
CFO, LivaNova

Excellent point. The reimbursement really read through immediately. Historically, we take 1%-2% inflationary price increases every year. This year, knowing that the reimbursement improvements are coming as of January 1, we were able to go in and renegotiate some of the volume-based contracts with accounts. That's actually translated immediately on the year-to-date basis, 200 to 300 basis of growth has been driven by realized price. We've essentially, our realized price has doubled relative to our historical inflationary increases.

The CORE-VNS is getting a lot of traction with the field. Now that it's actually published, we're able to take that data and talk about it explicitly with clinicians. That has translated into a new patient identification funnel that is very robust. We've seen that continue to increase over the course of the year, and that's now converting into volume. We are seeing both volume and realized price play a significant role in driving growth for this year. We see that continuing into next year and beyond.

Ahmet Tezel
Chief Innovation Officer, LivaNova

Can I add a couple of things? On the CORE-VNS, I think the most important thing to remember is, we achieved high 70s seizure reduction, but more than or about 50% of the patients were super responders, and super responders are defined as 80% seizure reduction or more. That was not something we could communicate prior to CORE-VNS data, because we were only able to utilize the data from the PMA study from 2005. At that time, the technology was very different. It didn't have certain features. For example, auto stimulation, and auto stimulation is when a seizure is coming, the device stimulates. Our original clinical data didn't have those capabilities. Now being able to communicate that is incredibly important. The last thing I'll say is, the next generation device that we're about to launch solves a fundamental workflow issue.

Today, when you get an epilepsy implant, you have to go to the physician's office 8x- 10 x for the first year, and then 1x-2x every other year. These people travel on average 40 mi, in rural areas up to 150 mi, and they have to be driven by a caregiver because even if they're adult, they don't have a driving license. With the next generation IPG, all of that happens remotely. We have a cloud-connected system now where the physician will be able to adjust the patient remotely from his or her office, and the patient will effectively communicate with the device through their phone.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

I know the LRP doesn't include depression. We haven't talked about that yet, but maybe you could give us an update on the studies, the submission, and when we could hear more about the potential for depression to be a commercial reality.

Ahmet Tezel
Chief Innovation Officer, LivaNova

Yeah. We've chosen the path with CMS to do what's called a draft submission. Rather than submitting your formal application and waiting for them to pick it off the pile and assess it, you do a draft submission. This gives an ability for CMS to interact with your submission and ask you questions. We've chosen that path. One of the key questions that CMS asked after our draft was, is the device durable in terms of therapy? Our RECOVER trial, which we designed together with CMS, is a five-year trial. The primary endpoint was at 12 months, but we finished three-year follow-up back in May of this year. One of the key questions CMS was, show us durability, and the three-year data just became available in May, which we are in the process of publishing it, but we also put it in public domain.

We submitted that recently to CMS. We have not heard back from them. It usually takes a couple of months for them to interact with new data. One possible outcome is they look at the three-year durability, which is exceptionally strong, and say, "Okay, we have no further questions." If that's the case, we go into a formal submission. Another alternative is they might come back and ask additional questions about that three-year durability data. That's where we are with CMS, and what we communicated to the street is, at the time of a formal submission, we will communicate that publicly.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Maybe, I know there was five, I think five different publications that went in around the depression study. Maybe you could just articulate what you think some of the stronger arguments are from some of those data subsets and the—

Ahmet Tezel
Chief Innovation Officer, LivaNova

Yeah.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

—submissions that were made.

Ahmet Tezel
Chief Innovation Officer, LivaNova

I mean, the most important piece is actual durability. Today, just to give the room a little bit of feedback about this patient population. In the trial, these patients were on average a 19-year major depressive episode. They have failed 13 different therapies, including interventional therapies. 40% of them tried suicide at least once, 70% were unemployed. This is a really, really sick population. Today, the only true alternative they have is either electroconvulsive therapy or transcranial magnetic stimulation, TMS. ECT is considered more standard of care. With ECT, you have to go 6x- 12 x under general anesthesia, and after you are a responder, the durability is not there. 50% of the patients fall off at 12 months. With VNS, because neuromodulation works better with time, at three years, we were at 80%. That is the biggest difference.

At three years, 80% still responder, versus with ECT, it is 50% loss at year one. Durability is probably the biggest differentiator. The other point I will make is that with this patient population, you are not trying to completely put them in remission. It is like, the analogy we use is that if you are a heart failure patient, the goal of your therapy is not for you to run a marathon. The goal of your therapy is to be able to climb a flight of stairs. With this patient population, we want even a partial response. Physicians consider extremely important, and partial response is defined as 30% reduction of your symptoms. We were able to demonstrate full response, partial response, durability in an extremely ill patient population, which makes us very excited about the data, particularly since there is no other true alternatives out there.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. We are right out of time, and maybe it is a good time to end there. We have a lot of exciting things in the pipeline, and we have a track meet to get to our next meeting. Thank you very much for your time, and thanks for your attention.

Alex Shvartsburg
CFO, LivaNova

Thank you, Matt. Thanks for having us.

Ahmet Tezel
Chief Innovation Officer, LivaNova

Thank you.